Ectopic expression of human mTOR increases viability, robustness, cell size, proliferation, and antibody production of chinese hamster ovary cells

Biotechnology and Bioengineering

Volumn 108, Issue 4, 2011, Pages 853-866

  Dreesen, Imke A J ^a   Fussenegger, Martin ^a,b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antibody; Biopharmaceutical manufacturing; Bioprocess engineering; Bioreactor; Biotechnology; Mammalian cells

Indexed keywords

ANTIBODY PRODUCTION; ANTIBODY TITERS; APOPTOSIS; BIOPHARMACEUTICAL MANUFACTURING; BIOPHARMACEUTICALS; BIOPROCESS ENGINEERING; BIOPROCESSES; CELL LINES; CELL SIZE; CELL-CYCLE PROGRESSION; CHINESE HAMSTER OVARY CELLS; ECTOPIC EXPRESSIONS; HUMAN THERAPEUTICS; MAMMALIAN CELLS; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); MANUFACTURING INDUSTRIES; OPTIMAL GROWTH; OVER-EXPRESSION; PRODUCTION CAPACITY; PRODUCTION CELLS; PROTEIN CONTENTS; PROTEIN THERAPEUTICS; SPECIFIC PRODUCTIVITY; TRANSGENE; TRANSGENICS;

ANTIBIOTICS; ANTIBODIES; BIOCHEMICAL ENGINEERING; BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE; CELL DEATH; ENGINEERING; GROWTH KINETICS; MAMMALS; OXYGEN;

MANUFACTURE;

GLYCOPROTEIN; GROWTH FACTOR; IMMUNOGLOBULIN G; MAMMALIAN TARGET OF RAPAMYCIN;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; APOPTOSIS; ARTICLE; BIOPROCESS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL ROBUSTNESS; CELL SIZE; CELL VIABILITY; CELLULAR PARAMETERS; CHO CELL; CONTROLLED STUDY; FEMALE; METABOLISM; NONHUMAN; OXYGEN SUPPLY; PHARMACEUTICAL ENGINEERING; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; SENSITIVITY ANALYSIS;

ANIMALS; ANTIBODY FORMATION; BIOREACTORS; BIOTECHNOLOGY; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; TOR SERINE-THREONINE KINASES;

CRICETULUS GRISEUS; MAMMALIA;

EID: 79952581899     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22990     Document Type: Article

References (60)

1. Al-Rubeai M, Singh RP. 1998. Apoptosis in cell culture. Curr Opin Biotechnol 9: 152-156.
2. Arden N, Betenbaugh MJ. 2004. Life and death in mammalian cell culture: Strategies for apoptosis inhibition. Trends Biotechnol 22: 174-180.
3. Arsham AM, Neufeld TP. 2006. Thinking globally and acting locally with TOR. Curr Opin Cell Biol 18: 589-597.
4. Astley K, Al-Rubeai M. 2008. The role of Bcl-2 and its combined effect with p21CIP1 in adaptation of CHO cells to suspension and protein-free culture. Appl Microbiol Biotechnol 78: 391-399.
5. Bailey JE. 1991. Toward a science of metabolic engineering. Science 252: 1668-1675.
6. Balcarcel RR, Stephanopoulos G. 2001. Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production. Biotechnol Bioeng 76: 1-10.
7. Birch JR, Racher AJ. 2006. Antibody production. Adv Drug Deliv Rev 58: 671-685.
8. Bowen JD, Petersdorf SH, Richards TL, Maravilla KR, Dale DC, Price TH, St John TP, Yu AS. 1998. Phase I study of a humanized anti CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 64: 339-346.
9. Castedo M, Ferri KF, Kroemer G. 2002. Mammalian target of rapamycin (mTOR): Pro- and anti-apoptotic. Cell Death Differ 9: 99-100.
10. Chaturvedi D, Gao X, Cohen MS, Taunton J, Patel TB. 2009. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 28: 1187-1196.
11. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105: 17414-17419.
12. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ. 2006. Hypothalamic mTOR signaling regulates food intake. Science 312: 927-930.
13. Dennis PB, Fumagalli S, Thomas G. 1999. Target of rapamycin (TOR): Balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 9: 49-54.
14. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. 2001. Mammalian TOR: A homeostatic ATP sensor. Science 294: 1102-1105.
15. Dinnis DM, James DC. 2005. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Biotechnol Bioeng 91: 180-189.
16. Dreesen IA, Charpin El-Hamri G, Fussenegger M. 2009. Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection. J Biotechnol 145: 273-280.
17. Edinger AL, Thompson CB. 2002. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288.
18. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. 2001. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945.
19. Fingar DC, Blenis J. 2004. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell-cycle progression. Oncogene 23: 3151-3171.
20. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487.
21. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. 2004. mTOR controls cell-cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216.
22. Fussenegger M, Schlatter S, Daetwyler D, Mazur X, Bailey JE. 1998. Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. Nat Biotechnol 16: 468-472.
23. Fussenegger M, Fassnacht D, Schwartz R, Zanghi JA, Graf M, Bailey JE, Pörtner R. 2000. Regulated cultivation of the survival factor bcl-2 in CHO cells increases viable cell density in batch culture and decreases DNA release in extended fixed-bed cultivation. Cytotechnology 32: 45-61.
24. Fux C, Mitta B, Kramer BP, Fussenegger M. 2004. Dual-regulated expression of C/EBP-alpha and BMP-2 enables differential differentiation of C2C12 cells into adipocytes and osteoblasts. Nucleic Acid Res 32(1): e1.
25. Gingras AC, Raught B, Sonenberg N. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826.
26. Grosshans BL, Ortiz D, Novick P. 2006. Rabs and their effectors: Achieving specificity in membrane traffic. Proc Natl Acad Sci USA 103: 11821-11827.
27. Heitman J, Movva NR, Hall MN. 1991. Targets for cell-cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909.
28. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. 2002. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signalling. FASEB J 16: 771-780.
29. Kahn BB, Myers MG, Jr. 2006. mTOR tells the brain that the body is hungry. Nat Med 12: 615-617.
30. Kaufmann H, Mazur X, Marone R, Bailey JE, Fussenegger M. 2001. Comparative analysis of two controlled proliferation strategies regarding product quality, influence on tetracycline-regulated gene expression, and productivity. Biotechnol Bioeng 72: 592-602.
31. Khoo SH, Al-Rubeai M. 2009. Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells. Biotechnol Bioeng 102: 188-199.
32. Koduri RK, Miller JT, Thammana P., 2001. An efficient homologous recombination vector pTV(I) contains a hot spot for increased recombinant expression in Chinese hamster ovary cells. Gene 280: 87-95.
33. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
34. Mahajan PB. 1994. Modulation of transcription of rRNA genes by rapamycin. Int J Immunopharmacol 16: 711-721.
35. Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG. 2008a. Enhancement of transient gene expression and culture viability using Chinese hamster ovary cells overexpressing Bcl-x(L). Biotechnol Bioeng 101: 567-578.
36. Majors BS, Arden N, Oyler GA, Chiang GG, Pederson NE, Betenbaugh MJ. 2008b. E2F-1 overexpression increases viable cell density in batch cultures of Chinese hamster ovary cells. J Biotechnol 138: 103-106.
37. Majors BS, Betenbaugh NJ, Pederson NE, Chiang GG. 2009. Mcl-1 overexpression leads to higher viabilities and increased production of humanized monoclonal antibody in Chinese hamster ovary cells. Biotechnol Prog 25: 1161-1168.
38. Martin DE, Hall MN. 2005. The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166.
39. Meents H, Enenkel B, Werner RG, Fussenegger M. 2002a. p27Kip1-mediated controlled proliferation technology increases constitutive sICAM production in CHO-DUKX adapted for growth in suspension and serum-free media. Biotechnol Bioeng 79: 619-627.
40. Meents H, Enenkel B, Eppenberger HM, Werner RG, Fussenegger M. 2002b. Impact of coexpression and coamplification of sICAM and antiapoptosis determinants bcl-2/bcl-x(L) on productivity, cell survival, and mitochondria number in CHO-DG44 grown in suspension and serum-free media. Biotechnol Bioeng 80: 706-716.
41. Papac DI, Briggs JB, Chin ET, Jones AJ. 1998. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis. Glycobiology 8: 445-454.
42. Peng RW, Fussenegger M. 2009. Molecular engineering of exocytic vesicle traffic enhances the productivity of Chinese hamster ovary cells. Biotechnol Bioeng 102: 1170-1181.
43. Peng T, Golub TR, Sabatini DM. 2002. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 22: 5575-5584.
44. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is a mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
45. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078.
46. Richter JD, Sonenberg N. 2005. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477-480.
47. Running-Deer J, Allison DS. 2004. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1 alpha gene. Biotechnol Prog 20: 880-889.
48. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. 2008. Science. 320: 1496-1501.
49. Santoro R, Lienemann P, Fussenegger M. 2009. Epigenetic engineering of ribosomal RNA genes enhances protein production. PLoS One 4: e6653.
50. Sarbassov DD, Ali SM, Sabatini DM. 2005. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-5603.
51. Schieke SM, Phillips D, McCoy JP, Aponte AM, Shen RF, Balaban RS, Finkel T. 2006. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxydative capacity. J Biol Chem 281: 27643-27652.
52. Schlatter S, Rimann M, Kelm J, Fussenegger M. 2002. SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alpha-amylase. Gene 282: 19-31.
53. Schlatter S, Senn C, Fussenegger M. 2003. Modulation of translation-initiation in CHO-K1 cells by rapamycin-induced heterodimerization of engineered eIF4G fusion proteins. Biotechnol Bioeng 83: 210-225.
54. Schmelzle T, Hall MN. 2000. TOR, a central controller of cell growth. Cell 103: 253-262.
55. Scolnik PA. 2009. mAbs: A business perspective. MAbs 1: 179-184.
56. Thomas G, Hall MN. 1997. TOR signalling and control of cell growth. Curr Opin Cell Biol 9: 782-787.
57. Tigges M, Fussenegger M. 2006. Xbp1-based engineering of secretory capacity enhances the productivity of Chinese hamster ovary cells. Metab Eng 8: 264-272.
58. Vézina J, Grossmüller F, Müller K. 2001. Influence of a transiently transfected gene on apoptosis, measurements guided by cotransfected GFP. J Immunol Meth 252: 163-169.
59. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84: 548-558.
60. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22: 1393-1398.